Good morning, Wake-Up Watchlisters! Happy national pasta day! Before you prep your noodle maker for the big day take a seat and let's review what's happening in the premarket. It's still earnings season with big names putting out reports this week. Bank of America (BAC) kicked things off this morning topping analysts' estimates and posting a positive surprise of $0.81 a share vs the expected $0.78. Still to come are Charles Schwab, (SCHW), Tesla (TSLA), Netflix (NFLX), and AT&T (T) among others. This week the Biden administration will be revealing the next step in its plan to reduce gasoline prices and China will release its third-quarter GDP figures, providing a key update on the second-largest economy in the world. The markets are green across the board, here's hoping they stay that way! The War Room is having a FREE Open House from Oct. 24-28 (9-4pm ET) Last time we did this, attendees had a chance to cash in 15 winners in five days... including an overnight double! FOR FREE! No catch... no delayed billing... no BS. Click here to sign up for the event now! Now, let's take a look at the top-moving stocks this morning. Acorda Therapuetics Inc. (Nasdaq: ACOR) Acorda Therapuetics Inc. is up 62.15% premarket. The company announced this morning that a three-judge panel has come to a decision in a dispute over licensing royalties relating to MS treatment, AMPYRA (dalfampridine). Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes PLC (Nasdaq: ALKS). Also, Acorda will no longer have to pay Alkermes any royalties for sales, licensing, and supply of AMPYRA. Leadership is confident this settlement will allow them to reduce the price of the treatment and help even more of the estimated 2.5 million people in the world who live with MS. Milestone Pharmacueticals (Nasdaq: MIST) Milestone Pharmaceuticals is up 36.16% premarket. This jump comes after the announcement this morning of positive results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray. The treatment promises to provide more affordable and accessible relief for patients with a type of abnormal heart rhythm called Paroxysmal Supraventricular Tachycardia (PSVT). This arrythmia affects an estimated 2 million people in the United States alone. We see pharmaceutical and healthcare companies like Milestone and Acorda making huge premarket moves all the time. Our friend and investing mastermind, Alexander Green has found a healthcare company with a technology he is calling "the most incredible investment opportunity in 37 years." Get in before the stock pops in the premarket and ends up on this list! |
No comments:
Post a Comment